-
-
Two men presented to a hospital in northwestern Missouri in June 2009 with fever, fatigue, diarrhea, thrombocytopenia and leukopenia. Both had a history of frequent recent tick bites. A novel phlebovirus was isolated in cell culture from patient blood. Electron microscopy revealed virus particles consistent with Bunyaviridae. Sequencing identified the viruses as novel members of the phlebovirus genus.
-
Patients who present with acute myocardial infarction (MI) complicated by cardiogenic shock represent a group at high risk for early mortality. Current guidelines recommend the use of intra-aortic balloon pump (IABP) for these patients, but there are few randomized, controlled trial data to support this.
-
Based on their review of prior published studies of telemedicine ICUs and the initiation of a telemedicine ICU in a Veterans Health Administration hospital system, the authors find that costs of implementation are substantial and the sum impact on hospital expenses and profits remains unclear.
-
The risk of interrupting prophylactic warfarin for stroke prevention in atrial fibrillation (AF) patients is unclear. Thus, these investigators from Denmark evaluated their national health registry and found 102,591 patients > age 30 with a first-time hospitalization for AF between 1997 and 2008.
-
Pediatric stroke remains one of the top 10 causes of death in children, with a mortality rate of 0.6 deaths per 100,000 strokes, and almost all of those affected have a residual neurologic deficit.
-
-
Rachmale and colleagues retrospectively identified 210 patients with acute lung injury/acute respiratory distress syndrome (ALI/ARDS) undergoing mechanical ventilation for longer than 48 hours.
-
Using a statewide administrative database and other sources, Gershengorn and colleagues examined data on all adult patients with a primary diagnosis of diabetic ketoacidosis (DKA) who were admitted to hospitals in the state of New York from 2005-2007.
-
In this issue: Side effects of finasteride; new ruling on pharmaceutical companies paying generic manufacturers; and FDA actions.
